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Abstract
Aims: Arrhythmogenic right ventricular cardiomyopathy (ARVC) is an inherited cardiomyopathy
characterized by ventricular arrhythmias and sudden death. Currently 60% of patients meeting
Task Force Criteria (TFC) have an identifiable mutation in one of the desmosomal genes. As much
overlap is described between other cardiomyopathies and ARVC, we examined the prevalence of
rare, possibly pathogenic sarcomere variants in the ARVC population.
Methods: One hundred and thirty-seven (137) individuals meeting 2010 TFC for a diagnosis of
ARVC, negative for pathogenic desmosomal variants, TMEM43, SCN5A, and PLN were screened
for variants in the sarcomere genes (ACTC1,MYBPC3,MYH7,MYL2,MYL3, TNNC1, TNNI3, TNNT2,
and TPM1) through either clinical or research genetic testing.
Results: Six probands (6/137, 4%)were found to carry rare variants in the sarcomere genes. These
variants have low prevalence in controls, are predicted damaging by Polyphen-2, and some of the
variants are knownpathogenic hypertrophic cardiomyopathymutations. Sarcomere variant carri-
ers had a phenotype that did not differ significantly from desmosomal mutation carriers. As most
of these probands were the only affected individuals in their families, however, segregation data
are noninformative.
Conclusion: These data show variants in the sarcomere can be identified in individuals with an
ARVC phenotype. Although rare and predicted damaging, proven functional and segregational
evidence that these variants can cause ARVC is lacking. Therefore, caution is warranted in inter-
preting these variants when identified on large next-generation sequencing panels for cardiomy-
opathies.
This is an open access article under the terms of the Creative Commons Attribution-NonCommercial License, which permits use, distribution and reproduction in any
medium, provided the original work is properly cited and is not used for commercial purposes.
c© 2018 The Authors. Journal of Cardiovascular Electrophysiology published byWiley Periodicals, Inc.
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1 INTRODUCTION
Arrhythmogenic right ventricular cardiomyopathy (ARVC) is an inher-
itedmyocardial disease characterized by fibrofatty replacement of the
myocardium. This results in a predisposition to often life-threatening
ventricular arrhythmias and functional alterations to the right and left
ventricles that can lead to the development of heart failure. A familial
pattern of disease can be recognized in up to 50% of cases, predom-
inantly inherited in an autosomal dominant manner.1 Reduced pene-
trance, and variable expressivity of presentation have complicated the
identification of a genetic cause in some cases.
ARVC is primarily thought of as a disease of the desmosome, or
the cell–cell junctions at the intercalated disk. Pathogenic variants in
five genes (DSP, PKP2, DSG2, DSC2, and JUP) are classically thought to
play a large role in ARVC pathogenesis.2,3 In routine clinical practice,
however, even in a well phenotyped population, up to 40% of ARVC
cases still elude identification of a genetic root cause.2,3 Because of the
importance of identifying those at risk for sudden death, gene finding
efforts have continued.
Increasingly, nondesmosomal genes have been implicated in ARVC
pathogenesis, such as CDH2 and CTNNA3.4,5 PLN has been identified
as a causative factor in a significant portion of individuals with ARVC
patients.3,6 Additionally, recent reports have identified SCN5A muta-
tions in a small percentage of ARVCpatients.7 Overlap betweenARVC
and dilated cardiomyopathy has been well described, and pathogenic
variants in sarcomere genes have been associated with DCM.8 Lit-
tle data exists, however, on the prevalence of other cardiomyopathy-
associated genes in the ARVCpopulation.9 In this study, we sequenced
an expanded panel of cardiac genes among individuals with a clini-
cal diagnosis of ARVC and without mutations in the ARVC-associated
genes PKP2, DSG2, DSP, DSC2, and JUP, or nondesmosomal TMEM43,
SCN5A, and PLN. We aimed to (1) assess the prevalence and
pathogenicity of sarcomere gene mutations in individuals with ARVC
without an identified desmosomal pathogenic variant and (2) compare
clinical characteristics and course between the two groups.
2 METHODS
2.1 Study population
Patients were eligible for inclusion if they were (1) diagnosed with
ARVC based on the 2010 diagnostic Task Force Criteria (TFC) for
ARVC,10 (2) were the family proband as defined as the first person
in the family to come to clinical attention and gain a clinical diagno-
sis of ARVC, (3) lacked a pathogenic/likely pathogenic variant in any of
the 5 desmosomal genes noted above, or TMEM43, PLN, or SCN5A, (4)
underwent broad cardiomyopathy gene screening as described below,
and (5) enrolled in the ARVC registries from the Johns Hopkins Uni-
versity and the Netherlands Heart Institute, a cardiovascular research
institute with collaborative participation of all eight Dutch University
Medical Centers. This study was approved by the JHSOM Institutional
Review Board.
2.2 Molecular genetic screening
Sequencing and deletion/duplication analysis of the nine most com-
mon sarcomere genes (ACTC1, MYBPC3, MYH7, MYL2, MYL3, TNNC1,
TNNI3, TNNT2, and TPM1, hereafter referred to as sarcomere genes)
were completed through a variety of methods: clinical genetic test-
ing, and research-lab based panel and exome sequencing. Within the
JHU registry, 92 patients underwent clinical cardiomyopathy panel
sequencing and deletion/duplication analysis, and 18 patients con-
sented to whole-exome sequencing using the Ilumina HiSeq2000 plat-
form. For exome sequencing, the human assembly GRCh37/hg19 was
used as reference genome. In the Dutch registry, 27 patients were
sequenced using a next-generation sequencing (NGS) panel consist-
ing of 209 genes (candidate genes and genes known to be involved
in cardiomyopathy). Therefore, in total 137 probands underwent
sequencing and deletion/duplication analysis of the sarcomere genes.
Nucleic acid deviations were compared with the reference sequence
for presence of variants in the sarcomere genes. All mutations were
confirmed by Sanger sequencing after polymerase chain reaction
amplification.
Potentially causal variants were identified using standard filtering
criteria as follows. Variantswere excluded if theyhad aminor allele fre-
quency (MAF) >0.1% in the Exome Aggregation Consortium Browser
(ExAC)11,12 and/or if they were present in dbSNP 126, 129, and 131.
Variants also were included if predicted damaging by Polyphen-2 and
below theMAF above.13 Variants were assessed and classified accord-
ing to the 2015 American College of Medical Genetics classification
criteria, as reported in Table 1.14 All patients and their families gave
informed consent for genomic DNA sample collection, storage, and
sequencing.
2.3 Phenotype evaluation
All individuals were phenotyped via medical records for diagnostic cri-
teria according to the 2010 TFC.10 A definite ARVC diagnosis was
characterizedby thepresenceof≥2major criteria, 1major and2minor
criteria, or 4 minor criteria. As indicated in Supplementary Table S1,
none of the individuals met diagnostic criteria for hypertrophic car-
diomyopathy of having a septal thickness of≥1.5 cm.15
2.4 Statistical analysis
Statistical analyses were performed using SPSS (version 22.0). All con-
tinuousdatawere calculatedasmeanandcategorical variables asnum-
bers (percentages). Variables were compared using the Fisher's exact
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TABLE 1 Variants in the sarcomere genes identified upon sequencing of 137 probands with ARVC
Family Gene Exon Amino acid change Nucleotide change % ExAC Polyphen (2)
ACMGpathogenicity
classification
1 MYH7 22 p.847_847del c.2541_2549del 0.0000% n/a VUS
2 21 p.Arg1500Gln c.4499G>A 0.0025% 0.999 VUS
3 37 p.Arg1846Cys c.5536C> T 0.0017% 1.000 VUS
4‡ 20 p.Arg723Cys c.2167C> T 0.0025% 0.995 P
5* MYBPC3 4 p.Gly148Arg c.442G>A 0.0042% 0.070 P
6† MYL3 4 p.Arg154His c.461G>A 0.0025% 0.861 LP
Note: Table 2 lists variants in sarcomere genes identified in the ARVC probands. ExAC frequencies as of 4/2017 are listed.11 Assessment of pathogenicity
according to criteria put forth by the American College of Medical Genetics is listed (LP = likely pathogenic; P = pathogenic; VUS = variant of uncertain
significance).14
‡Segregatedwith disease in relatives frommultiple families. (ClinVar: http://www.ncbi.nlm.nih.gov/clinvar/variation/14095/).
*This variant is a lowpenetrance variant and frequently observed in theDutchHCMpopulation. It is a foundermutation and creates a cryptic splice acceptor
site (P. Van Tintelen, personal communication). Prediction programs (Polyphen-2) are not valid because of supposed pathogenic splice site effect. Aberrant
splicing is demonstrated in two university hospitals. This individual also carried a variant in LMNA c.1003C> T; p.Arg335Trp that has been described as likely
pathogenic.19
†This mutation has been demonstrated to cause a disturbed binding tomyosin in vitro.16




In total, 137 individuals meeting diagnostic criteria for ARVC under-
went sequencing of the sarcomere genes. Sarcomere variants identi-
fied are described in Table 1. These variants were rare in ExAC (<0.1%
as described above). A total of six variants were identified in 6/137
(4.3%) separate probands. Variants were identified inMYH7,MYBPC3,
and MYL3. Variants in MYH7 included three missense mutations in
MYH7 and one in-frame deletion. There was one missense variant
identified in MYBPC3 and one variant in MYL3. For most families, the
proband was the only reported affected in the family. In one family
(Individual #2 as described in Table 2), the variant was identified in her,
and also in her mother who had met diagnostic criteria for ARVC with
T wave inversions through V3 on ECG and over 500 PVCs on Holter
monitoring. The variant identified in MYH7 was previously published
in the literature segregating with HCM in multiple families.16 For the
other four families, family screening was not completed or cardiac
screening, including ECG, Holter monitoring, and either echocardio-
gram and/or cardiac MRI in first degree relatives was within normal
limits. As noted in Table 1, many of these variants may not meet
pathogenicity criteria for a pathogenic call when classified according
to the ACMG criteria; however, would still be reported. Even those
that may be classified as pathogenic for a diagnosis of HCM may not
be reported as pathogenic for a diagnosis of ARVC given the lack of
evidence for disease association.
3.2 Clinical evaluation
All individuals met diagnostic criteria as described in Table 2.10 Com-
pared to previously published ARVC patients carrying desmosomal
mutations, individuals with sarcomere variants tended to be slightly
older (36.8 years of age vs. 33.2 years of age), though not significant.2
Clinical characteristics of the study population were compared to
previously published values2 in desmosomal mutations (definitions
in Supplementary Table S2): gender, type of presentation, syncope,
inducibility at electrophysiology study, premature ventricular con-
traction (PVC) count on 24-hour ambulatory monitoring (Holter),
ICD placement, appropriate ICD therapy, ventricular tachycardia (VT)
storm, VT ablation, and left ventricular dysfunction (left ventricular
ejection fraction below 50%), heart failure, and transplant. Individu-
als with ARVC carrying sarcomere variants were more likely to have
undergone a VT ablation (P = 0.009), but otherwise had a similar
disease presentation and course to desmosomal mutation carriers.
Figure 1 shows the ECG and cardiac MRI short axis image of individ-
ual 3, showing characteristic T wave inversions across the precordium
anddyskinetic basal right ventricular (RV) freewall with enhancement,
suggestive of a diagnosis of ARVC. Supplementary Table S1 describes
septal thickness; all values were way below the threshold for HCM.
4 DISCUSSION
It hasbeenwell documented that approximately40–60%of individuals
meeting diagnostic criteria for ARVC have a mutation mainly in genes
encoding the cardiac desmosome.2,3 The availability of tools such as
whole-exome sequencing and expansion of number of genes included
on clinical cardiomyopathy panels has opened the doors for further
gene discovery, but has also introduced significant challenges in coun-
seling patients for genetic testing, and in interpretation of variants for
the clinician. Understanding the pathogenicity of a variant is critical in
the identification of those at risk for sudden death and implementing
risk-stratifying cascade screening.
In this cohort, we describe that a small but significant per-
centage (4.3%) of individuals with ARVC may have putative likely
pathogenic/pathogenic variants reported in the sarcomere genes. A















TABLE 2 Clinical characteristics of the 6 patients identified to have pathogenic sarcomere variants
Clinical presentation ECG or SAECG Structure













1 M 50 + Sympt + M n/a M +
2 F 14 + Sympt + M – M +
3 M 27 + Sympt + M – M –
4 M 26 + Sympt + m – M +
5 M 28 + Sympt – M m M +




inducibility Sustained VA VT storm ICD implant ICD therapy VT ablation Heart failure
Death/cardiac
transplant Follow-up (years) TFC
n/a + + + + + + + + 23
6(D)
470 + + (At presentation) – + + + + – 20
4(D)
n/a + + (At presentation) + + + + – – 27
6(D)
472 + + – + + + – – 14
5(D)
n/a + + (At presentation) – + + – – – 6
9(D)
1181 n/a + – – – – – – 13
4(D)
AA = antiarrhythmic; B = borderline; D = definite; EP = electrophysiology; F = female; ICD = implantable cardiovertor defibrillator; LV dysfunction = LV EF ≤50%; M =male; m =minor abnormality as per the 2010
ARVC revised Task Force Criteria;M=major abnormality as per the 2010 ARVCRevised Task Force Criteria; Sympt= symptomatic with chest pain, dyspnea, palpitations, presyncope, or syncope; TFC= 2010 revised
Task Force Criteria for the diagnosis of ARVC; VA= ventricular arrhythmias including VT and VF; VT /VF= ventricular tachycardia/ventricular fibrillation.
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F IGURE 1 Electrocardiogramand cardiacMRI of proband #3 showingmajor criterion of Twave inversions across the precordiumand dyskinetic
base and enhancement of the RVwall [Color figure can be viewed at wileyonlinelibrary.com]
systematic functional studies or extensive segregation in affected indi-
viduals on each of these rare novel variants, however, it is difficult to
determine the role these variants play in the ARVC phenotype of indi-
viduals. Integration of segregation analysis in families with ARVC is
also challenging given thewell described reducedpenetrance.3 In addi-
tion, mounting exome population data over the years have led to sys-
tematic reclassification of previously described pathogenic variants in
the cardiomyopathies as uncertain, or even benign.17 Therefore, we as
well as other centers are hesitant to immediately label these variants
as “pathogenic” given the implications for cascade screening in these
families. Given this, without further evidence, sarcomere variants
should not be used to guide presymptomatic screening in families with
ARVC.
Continued genetic overlap between the cardiomyopathies has been
described, and it follows that structural heart disease with arrhyth-
mias that primarily affects the RV may produce a phenotype mimick-
ing ARVC.4,10 Indeed, these individuals with sarcomere variants meet
TFC for ARVC, and do not have significant differences in structural dis-
ease than desmosomal variant carriers. The cohort reported here is
less likely to have a reported family history of disease than previous
reported prevalences in desmosomal mutation carriers.2 They have no
significant differences in phenotype by TFC, do not meet HCM crite-
ria, but also, importantly, they donot have any significant differences in
clinical course (other than being more likely to undergo catheter abla-
tion, which is by physician judgment) than previously described indi-
viduals with ARVCwith desmosomal mutations.2 These are important
findings as it indicates that these individuals are not misdiagnosed, in
fact, they have similar phenotype and clinical course, confirming that
these individuals do indeed have ARVC.
This study is limited in that most individuals are the only one
affected in their family, so familial segregation is not informative.
Unfortunately, due to family choice, prospective information on family
screening could not be obtained. Negative family history is not unusual
in ARVC, as reduced penetrance is well described.3 Additionally, as
with most cardiomyopathy variants, functional data are lacking for
the majority of the variants identified here. These sarcomere variants
may have a pathogenic role, since there is some (in silico) functional
evidence, cosegregation with HCM in prior publications, and altered
splicing for one of these variants.14,18 At this time, however, as conclu-
sive data of a role in ARVC are lacking, this analysis provides important
information to clinicians whomay order large-scale sequencing panels
that caution is advised when sarcomere variants are resulted in a
patient with an ARVC phenotype. Even if a variant is reported as
pathogenic/likely pathogenic due to limited functional data, these data
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suggest that sarcomere variants should not be interpreted or used
clinically as pathogenic in ARVC families.
5 CONCLUSION
Despite these limitations, the results of our study highlight that a small
proportion of patients exhibiting an ARVC phenotype may have vari-
ants identified in the sarcomere genes. This provides important addi-
tional evidence for clinical practice to recommend caution in inter-
pretation of comprehensive cardiomyopathy gene testing results in
genetic screeningofARVCpatients. At this point,without further func-
tional studies or strong segregation with disease in multiple families,
these variants should not be used for clinical care. In addition, the iden-
tification of these variants, yet absence of evidence of a causative role,
highlights the importance of cardiac genetics expertise in the interpre-
tation of these large cardiomyopathy panels in families with inherited
heart disease.
Further work would be of great interest to investigate the func-
tional role of these variants in the function of the sarcomere and
the desmosome, and in the pathogenesis of ARVC. Until then, these
variants should not be utilized in clinical decision making, or family
screening.
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